There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Globus Medical (GMED – Research Report), DocGo (DCGO – Research Report) and Codexis (CDXS – Research Report) with bullish sentiments.
Globus Medical (GMED)
In a report released today, Mathew Blackman from Stifel Nicolaus maintained a Buy rating on Globus Medical, with a price target of $61.00. The company’s shares closed last Wednesday at $53.16.
According to TipRanks.com, Blackman is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Globus Medical with a $65.18 average price target, implying a 20.5% upside from current levels. In a report issued on December 19, Canaccord Genuity also maintained a Buy rating on the stock with a $71.00 price target.
See the top stocks recommended by analysts >>
DocGo (DCGO)
In a report released today, David Grossman from Stifel Nicolaus maintained a Buy rating on DocGo, with a price target of $12.00. The company’s shares closed last Wednesday at $5.53, close to its 52-week low of $4.80.
According to TipRanks.com, Grossman is a 5-star analyst with an average return of
DocGo has an analyst consensus of Strong Buy, with a price target consensus of $12.40.
Codexis (CDXS)
Stifel Nicolaus analyst Daniel Arias maintained a Buy rating on Codexis today and set a price target of $5.00. The company’s shares closed last Wednesday at $3.37.
According to TipRanks.com, Arias is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Currently, the analyst consensus on Codexis is a Moderate Buy with an average price target of $5.67, implying a 68.2% upside from current levels. In a report issued on December 14, Craig-Hallum also assigned a Buy rating to the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on GMED:
- Globus Medical price target raised to $58 from $53 at Truist
- Globus Medical price target raised to $71 from $67 at Canaccord
- Globus Medical price target lowered to $53 from $60 at Morgan Stanley
- Globus Medical price target lowered to $53 from $58 at Truist
- Globus Medical backs FY23 EPS view $2.30, consensus $2.32
